Bristol Myers Squibb, Acceleron rack up second OK for Reblozyl, onto blockbuster status
Reblozyl, the anemia drug Celgene paid a modest $25 million upfront to partner on 9 years ago, brought Bristol Myers Squibb one of only two new drug approvals in 2019. Merely five months later, it’s taking home another supplemental OK expected to catapult sales into blockbuster territory.
The FDA has approved Reblozyl (luspatercept) as a treatment for anemia in a subset of adults with lower-risk myelodysplastic syndromes. Specifically, it’s limited to patients who have failed an erythropoiesis stimulating agent and require 2 or more red blood cell units over 8 weeks. These MDS patients are further characterized by ring sideroblasts, where iron accumulates in the mitochondria of red blood cells, rendering them dysfunctional.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
